TI
PRVL

Trexquant Investment’s Prevail Therapeutics Inc. Common Stock PRVL Stock Holding History

Trexquant Investment’s Portfolio PRVL Stock Details PRVL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-19,910
Closed -$203K – 1660
2020
Q3 		$203K Buy
+19,910
New +$267K 0.01% 1075

Other funds holding PRVL

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TAL
TIG Advisors LLC New York $2.16B AUM 72.99% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Trexquant Investment's PRVL Position: Q4 2020 in Review

Trexquant Investment sold out of Prevail Therapeutics Inc. Common Stock (PRVL) in Q4 2020, closing a stake of 19,910 shares — an estimated $203K sold.

Trexquant Investment first reported a position in PRVL in Q3 2020 and held it in 1 quarter. The position peaked at $203K in Q3 2020. 93 funds tracked by Wall St. Rank hold PRVL as of Q4 2020.

  • Trexquant Investment reported no remaining Prevail Therapeutics Inc. Common Stock position as of Q4 2020 after selling out during the quarter.
  • Trexquant Investment sold 19,910 Prevail Therapeutics Inc. Common Stock shares in Q4 2020, an estimated $203K.
  • Trexquant Investment first reported a position in Prevail Therapeutics Inc. Common Stock in Q3 2020 and held it in 1 quarter.
  • Trexquant Investment's Prevail Therapeutics Inc. Common Stock position peaked at $203K in Q3 2020.
  • 93 funds tracked by Wall St. Rank held Prevail Therapeutics Inc. Common Stock as of Q4 2020.

Based on Trexquant Investment's 13F filing for Q4 2020, filed 11 Feb 2021.